MK 0429

Drug Profile

MK 0429

Alternative Names: MK 0429; MK-429

Latest Information Update: 23 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 03 Oct 2007 Data presented at the American Society for Bone and Mineral Research 29th Annual Meeting (ASBMR-2007) added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections
  • 31 Mar 2006 Phase-I clinical trials in Prostate cancer in France (PO)
  • 31 Mar 2006 Phase-I clinical trials in Prostate cancer in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top